Journal
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 75, Issue 1, Pages 15-26Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2009.09.008
Keywords
Metastatic colorectal cancer; Management; Cytotoxic drugs; Cetuximab; Bevacizumab
Categories
Ask authors/readers for more resources
The prognosis of patients with metastatic colorectal cancer has significantly improved in the last few years, with the introduction into the clinical practice of new cytotoxic treatments, the availability of non-cross resistant agents after the front-line treatment failure, and the combination of targeted agents (i.e., the inhibitors of the epidermal growth factor and vascular endothelial growth factor pathways) with conventional drugs. All these options must be incorporated into a complex strategy of management, in which a customized management according to the disease status, with an intensified induction approach followed by maintenance (and reinduction), should be investigated. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available